{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:22Z","timestamp":1781650642167,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) have transformed outcomes in microsatellite instability-high (MSI-H) deficient mismatch repair (dMMR) cancers. The influence of germline MMR gene variants on ICI remains unclear. In this single-center study, 93 patients with Lynch syndrome-associated MSI-H\/dMMR digestive cancers received ICI monotherapy or combination therapy. Germline MMR variants were classified, and progression-free survival (PFS) was evaluated by gene and variant type. Most patients carried\n                    <jats:italic>MLH1<\/jats:italic>\n                    or\n                    <jats:italic>MSH2<\/jats:italic>\n                    variants. At 24 months, estimated PFS was 81.5% for\n                    <jats:italic>MLH1<\/jats:italic>\n                    , 67.2% for\n                    <jats:italic>MSH2\/EPCAM<\/jats:italic>\n                    , and 78.6% for\n                    <jats:italic>MSH6<\/jats:italic>\n                    , with no PFS events in\n                    <jats:italic>MLH1<\/jats:italic>\n                    promoter methylation or\n                    <jats:italic>PMS2<\/jats:italic>\n                    subgroups. No statistically significant differences in PFS were observed between gene groups. Performance status\u2009\u2265\u20092 was the only factor associated with poorer PFS. Neither MMR gene type nor variant class significantly influenced ICI efficacy in Lynch syndrome-related MSI-H\/dMMR digestive cancers, supporting the use of ICIs regardless of germline MMR genotype.\n                  <\/jats:p>","DOI":"10.1186\/s13053-026-00339-w","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:38:04Z","timestamp":1776519484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of germline MMR gene variants on immune checkpoint inhibitors response in patients with MSI-H\/dMMR digestive cancers: a retrospective cohort analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Antoine","family":"Dardenne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Loisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pellat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Metras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Samaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Parc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"23","key":"339_CR1","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"10476","key":"339_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383\u201395.","journal-title":"Lancet"},{"issue":"10","key":"339_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","volume":"22","author":"P Johannet","year":"2025","unstructured":"Johannet P, Rousseau B, Aghajanian C, Foote MB, Diaz LA. Therapeutic targeting of mismatch repair-deficient cancers. Nat Rev Clin Oncol. 2025;22(10):734\u201359.","journal-title":"Nat Rev Clin Oncol"},{"key":"339_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","volume":"187","author":"P Manca","year":"2023","unstructured":"Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani MM, et al. Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2023;187:15\u201324.","journal-title":"Eur J Cancer"},{"issue":"18","key":"339_CR5","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-22-3964","volume":"29","author":"C Gallois","year":"2023","unstructured":"Gallois C, Landi M, Taieb J, Sroussi M, Saberzadeh-Ardestani B, Cazelles A, et al. Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors. Clin Cancer Res. 2023;29(18):3771\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"339_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","volume":"34","author":"T Ratovomanana","year":"2023","unstructured":"Ratovomanana T, Nicolle R, Cohen R, Diehl A, Siret A, Letourneur Q, et al. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2023;34(8):703\u201313.","journal-title":"Ann Oncol"},{"key":"339_CR7","unstructured":"Randrian V, et al. The mechanism of mismatch repair deficiency informs survival outcomes derived from immune checkpoint blockade across MMRd solid tumors. Poster presented at: ESMO Congress 2025; 2025 Oct 17\u201321; Berlin, Germany."},{"issue":"9","key":"339_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/oncolo\/oyad082","volume":"28","author":"R Colle","year":"2023","unstructured":"Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, et al. BRAF V600E\/ RAS mutations and lynch syndrome in patients With MSI-H\/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors. Oncologist. 2023;28(9):771\u20139.","journal-title":"Oncologist"},{"issue":"7","key":"339_CR9","doi-asserted-by":"publisher","first-page":"100757","DOI":"10.1016\/j.modpat.2025.100757","volume":"38","author":"NC Helderman","year":"2025","unstructured":"Helderman NC, Strobel F, Bohaumilitzky L, Terlouw D, Van Der Werf \u2019T, Lam AS, Van Wezel T, et al. Lower degree of microsatellite instability in colorectal carcinomas from MSH6-associated lynch syndrome patients. Mod Pathol. 2025;38(7):100757.","journal-title":"Mod Pathol"},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"104668","DOI":"10.1016\/j.yexmp.2021.104668","volume":"122","author":"-T Bajwa","year":"2021","unstructured":"Bajwa -T, Broeke SW, Ballhausen A, Ahadova A, Suerink M, Bohaumilitzky L, Seidler F, et al. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer. Experimental Mol Pathol ct. 2021;122:104668.","journal-title":"Experimental Mol Pathol ct"},{"issue":"10","key":"339_CR11","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1002\/ijc.33115","volume":"147","author":"ME Salem","year":"2020","unstructured":"Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability\u2010high solid tumors. Intl J Cancer. 2020;147(10):2948\u201356.","journal-title":"Intl J Cancer"},{"issue":"9","key":"339_CR12","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/1078-0432.CCR-23-3004","volume":"30","author":"MM Khushman","year":"2024","unstructured":"Khushman MM, Toboni MD, Xiu J, Manne U, Farrell A, Lou E, et al. Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations. Clin Cancer Res. 2024;30(9):1906\u201315.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"339_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/PAS.0000000000000606","volume":"40","author":"A Kato","year":"2016","unstructured":"Kato A, Sato N, Sugawara T, Takahashi K, Kito M, Makino K, et al. Isolated Loss of PMS2 immunohistochemical expression is frequently caused by heterogenous MLH1 promoter hypermethylation in lynch syndrome screening for endometrial cancer patients. Am J Surg Pathol. 2016;40(6):770\u20136.","journal-title":"Am J Surg Pathol"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"113253","DOI":"10.1016\/j.ejca.2023.113253","volume":"192","author":"JH Yu","year":"2023","unstructured":"Yu JH, Xiao BY, Tang JH, Li DD, Wang F, Ding Y, et al. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients. Eur J Cancer. 2023;192:113253.","journal-title":"Eur J Cancer"},{"issue":"16suppl","key":"339_CR15","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1200\/JCO.2025.43.16_suppl.10504","volume":"43","author":"V Randrian","year":"2025","unstructured":"Randrian V, Artz O, Abbass M, Harrold E, Foote MB, Cercek A, et al. Gene-specific outcomes in patients with Lynch syndrome treated by immune checkpoint blockade for advanced cancer. JCO. 2025;43(16suppl):10504\u201310504.","journal-title":"JCO"},{"key":"339_CR16","doi-asserted-by":"crossref","unstructured":"Ali-Fehmi R, Krause HB, Morris RT, Wallbillich JJ, Corey L, Bandyopadhyay S, et al. Analysis of concordance between next-generation sequencing assessment of microsatellite instability and immunohistochemistry-mismatch repair from solid tumors. JCO Precis Oncol. 2024;(8):e2300648.","DOI":"10.1200\/PO.23.00648"},{"issue":"3","key":"339_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1053\/j.gastro.2021.05.007","volume":"161","author":"T Ratovomanana","year":"2021","unstructured":"Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, et al. Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair. Gastroenterol sept. 2021;161(3):814\u2013e8267.","journal-title":"Gastroenterol sept"},{"issue":"12","key":"339_CR18","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/sj.bjc.6605988","volume":"103","author":"JF You","year":"2010","unstructured":"You JF, Buhard O, Ligtenberg MJL, Kets CM, Niessen RC, Hofstra RMW, et al. Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer. 2010;103(12):1840\u20135.","journal-title":"Br J Cancer"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00339-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:21:42Z","timestamp":1781648502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00339-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00339-w","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The database was approved by the ethics committee (CER-2024-AMARA-ImmunoMSI - MS1.0-00267). The cohort study was approved by the ethics committee (N\u00b02020 \u2013 CER 2020-6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Anna Pellat has received consulting fees from Servier, MSD, Amgen, and Merck; a travel grant from Ipsen and Merck; and has a non-remunerated interest as a member of the Fondation Fran\u00e7aise de Canc\u00e9rologie Digestive, Groupe des Tumeurs Neuroendocrines, and the ESMO Real-World Data and Digital Health Group. Thomas Samaille has received honoraria and congress fees from Merck Serono. Roman Cohen has received honoraria from AstraZeneca\/Daiichi Sankyo, Bristol-Myers Squibb, MSD Oncology, and Servier, as well as congress and travel fees from Bristol-Myers Squibb, MSD Oncology, and Servier. Thierry Andre has received consulting fees or honoraria from AbbVie, Aptitude Health, Biocartis, Bristol-Myers Squibb, GlaxoSmithKline, MSD Co., Inc., Medicenna, Nimbus, Sanofi, Seagen, Servier, Takeda, and Pfizer. He has also served as a data monitoring committee member for Inspirna and received support for meetings from Bristol-Myers Squibb, Merck & Co. Inc., and Takeda. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}